June 26 (Reuters) - Prima Biomed Ltd (PRR)
- Operational update
- Says is pleased to advise that clinical studies of IMP321 are progressing well
- Says final results of 15 patients from safety run-in phase of aipac are expected in q4 of 2017
- Says data from three cohorts related to the tacti-mel trial is expected in h1 2018
News: PRR Prima BioMed says clinical studies of IMP321 are progressing well
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.005(1.35%) |
Mkt cap ! $522.9M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.5¢ | $299.2K | 829.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 32681 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 38380 | 17 |
View Market Depth
| Last trade - 15.11pm 26/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |